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Abstract
Purpose To investigate the sensitivity of the color vision test by Arden in patients with dysthyroid optic neuropathy (DON) 
to improve diagnosis.
Methods In this observational, retrospective study, we included the medical records of 92 eyes (48 patients) with diagnosis 
of DON between 2008 and 2019 in order to evaluate the full spectrum of findings from the color vision test by Arden, and 
to determine potential importance of this test. Thirty-five patients were female, and 13 patients were male. The mean age 
was 58.0 years (range: 34–79) at the time of the DON diagnosis.
Results Forty-one eyes displayed relatively good BCVA with ≤ 0.2 LogMAR. We found a protan value exceeding the thresh-
old of ≥ 8% in 57 eyes (30 patients) at the time of the diagnosis. The sensitivity of protan was 61.9% (95% CI 51.2–71.8%), 
while that of tritan was a striking 98.9% (95% CI 94.1–99.9%).
We discovered one pathological sign, tritan deficiency (based on a threshold of ≥ 8%) consistently in all eyes but one at the 
time of the diagnosis, regardless of the visual field defects or any changes in best-corrected visual acuity (BCVA).
Conclusion We found blue-yellow (tritan) deficiency, to be a sensitive and reliable indicator of dysthyroid optic neuropathy. 
We conclude that, in cases with suspected DON, a color vision test that can detect tritan deficiency is an essential tool for 
the adequate assessment, diagnosis, and treatment of DON.
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Introduction
Thyroid-associated orbitopathy (TAO) is the most com-
mon manifestation of Graves’ disease, affecting 25–50% of 
patients with the condition [1]. TAO presents as an orbital 
inflammation leading to an enlargement of the extraocular 
muscles and proliferation of the orbital fat, which, in turn, 
result in exophthalmos, impairment of the ocular motility, 
eye lid retraction, and, in severe cases, compression of 
the optic nerve. About 40% of the patients with Graves’ 
disease suffer from a simultaneous manifestation of ocular 
and systemic symptoms [2, 3].
Dysthyroid optic neuropathy (DON) is another serious 
complication of TAO, observed in 4–8% of the patients 
[4, 5]. Although considered self-limiting, with an active 
phase lasting up to 24 months, followed by an inactive 
phase, DON still needs to be diagnosed in a timely manner 
to prevent the vision loss.
According to the Consensus Statement of the Euro-
pean Group on Graves’ Orbitopathy (EUGOGO), DON is 
described as sight-threatening TAO and/or corneal break-
down requiring immediate intervention to preserve vision 
[6]. In most cases, the diagnosis of DON is quite chal-
lenging due to the multifactorial causes of visual acuity 
impairment in TAO patients.
This study seeks to identify the potential pathological 
signs of DON by analyzing the full spectrum of findings 
from color vision tests in a large group of patients. The 
ultimate goal is to aid early diagnosis of DON and to allow 
for its timely treatment.
Patients and methods
Patients
This observational, retrospective, cross-sectional study 
was conducted in the Department of Ophthalmology, Lud-
wig-Maximilians-University, Munich, Germany. For this 
type of study, formal consent is not required. All proce-
dures performed in this study were in accordance with the 
ethical standards of the institutional research committee 
and with the Helsinki declaration and its later amendments 
orcomparable ethical standards. We obtained approval 
from the Ethics Committee of the Ludwig-Maximilians-
University, Munich, Germany.
We examined the medical charts of all patients given 
a definitive diagnosis of DON in the Plastic and Recon-
structive Surgery Section between 2008 and 2019. Our 
sample included 48 patients and 92 eyes. We compiled 
and analyzed the data with SPSS version 25.0 (SPSS Inc., 
Chicago, IL, USA).
The definitive diagnosis of DON was based on the pres-
ence of one or more of the following clinical findings, 
confirmed by a senior ophthalmic plastic consultant (CH): 
(i) worsening of best-corrected visual acuity (BCVA) in 




Many studies have examined clinical features of DON, and documented changes in color vision in patients 
with this condition. Yet, these changes have not been systematically evaluated to date and we still do not 
know the characteristics and the sensitivity of the changes in color vision in patients with DON.
We discovered one pathological sign, tritan deficiency (based on a threshold of ≥ 8%), consistently in all 
eyes but one to be positive at the time of the diagnosis, regardless of the visual field defects or any changes 
in best corrected visual acuity (BCVA).
Interestingly, 41 eyes out of 92 eyes displayed relatively good BCVA with ≤ 0.2 LogMAR and also 7 
eyes had no VF defects in our case series.
Blue-yellow (tritan) deficiency is a sensitive indicator of dysthyroid optic
 neuropathy.
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comparison to the prior visit (≥ 2 lines) and/or (ii) BCVA 
with pinhole being ≤ 0.6 (decimal), but not due to corneal 
problems or other pre-existing eye diseases; (iii) a positive 
swinging-flash-light test or relative afferent pupillary defect 
(RAPD); (iv) optic disc edema; or (v) findings of apical 
crowding in orbital computerized tomography (CT).
We included only the patients with an existing color 
vision test by Arden at the time of the diagnosis of DON, 
which allowed us to evaluate patterns of protan and tritan 
deficiency in DON patients.
Exclusion criteria were corneal pathologies including sig-
nificant keratopathy, which potentially affect the outcome of 
the color vision test; history of corneal or glaucoma surgery; 
nystagmus; other causes of optic neuropathy; and coexisting 
ocular diseases such as amblyopia, retinal pathologies, and 
significant cataract as documented in the medical records.
In all patients, a complete ophthalmic examination was 
performed including BCVA assessed in decimals, obtained 
with a Snellen projection chart at a distance of 6 m, and 
documented as LogMAR function for statistical analy-
sis. In addition, slit-lamp biomicroscopy, ocular motility, 
measurement of proptosis with Hertel exophthalmometry, 
relative afferent pupillary defect or swinging-flash-light 
test (SWFLT), and indirect ophthalmoscopy were recorded. 
Assessment of the activity of Graves’ orbitopathy (GO) was 
done according to the European Group on Graves’ Orbitopa-
thy (EUGOGO) recommendations with the clinical activity 
score (CAS) including 7 items at the first visit and 10 items 
at the following visits (ocular or retrobulbar pain, pain with 
eye movement, erythema of the eye lids, swelling of the eye 
lids, redness of the conjunctiva, chemosis of the conjunc-
tiva, swelling/erythema of caruncle, increase in proptosis 
(≥ 2 mm), worsening of extraocular muscle motility in any 
one direction (> 8°), and/or worsening of visual acuity (≥ 1 
line decrease in Snellen chart) [7].
Color vision test by Arden
In all patients, a computerized color vision test by Arden 
was performed. In this examination, a 21-inch. color moni-
tor was used to present 10 random letters (A, E, H, M, O, T, 
U, V, X, and Y) for 200 ms in the middle of the monitor to 
patients from a distance of 1.5 m. The letters have an equal 
luminance with the background and can only be recognized 
due to their difference in hue from the background. In this 
method, three color axes—red (protan), green (deutan), and 
blue (tritan)—can be tested. The color vision test self-cal-
ibrating is also additionally being calibrated and checked 
every 6 months by a professional. After the test, a modified 
binary search is carried out to identify the threshold color 
contrast. According to Berninger et al., the threshold for 
the tritan and protan axes should not exceed 8% in healthy 
probands [8]. According to their work, protan and deutan 
results were comparable; therefore, only the data for pro-
tan and tritan was collected. Accordingly, in our study, we 
considered protan and tritan to be pathological if the tested 
threshold was ≥ 8.0%.
Table 1  Demographic data for all included patients and clinical data 
for all included eyes
TRAB TSH-receptor antibody, TSH thyroid-stimulating hormone, 
BCVA best-corrected visual acuity, CAS clinical activity score, RAPD 
relative afferent pupillary defect
Characteristic n (%)/mean (range)
All 48 (92 eyes)
Patient demographic data










TSH (µU/mL) 3.7 (0–34.0)
Clinical data for all included eyes
BCVA (LogMAR) 0.42 (0–2.0)
CAS 5.6 (1–8)
Visual field mean deviation (dB)  − 8.1 (− 32.9 to 1.3)












 ≥ 8.0% 57 (30 patients)
 < 8.0% 35 (18 patients)
Sensitivity 61.9% (95% CI [51.2–71.8%])
Tritan 41.6% (6.3–100.0)
 ≥ 8.0% 91 (48 patients)
 < 8.0% 1
Sensitivity 98.9% (95% CI [94.1–99.9%])
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Arden color vision test was described by Arden et al. in 
1988 [9, 10]. At their first published preliminary results, the 
authors described a computer graphics system, which calcu-
lates the values of red, green, and blue signals and specifies 
them in Commitè Internationale d’ Eclairage (CIE) X, Y, 
and Z fundamentals, so the changes in chrominance hap-
pen without any changes in luminance. Also, the authors 
argued that this method has the main advantage of patients 
being presented with graduated and constantly changing 
hues in which no alterations of luminance occur. The other 
advantages are this method being self-calibrating and auto-
mated, avoiding operator error and also the difficulties of 
interpretation.
Also, it is important to mention that there is a possible 
effect of aging on color vision. As an example, Barbur et al. 
showed that thresholds for pathology increase about 1% per 
year for red-green and about 1.6% for blue-yellow past the 
age of 20 years [11]. However, there are two other researches 
arguing that there are no age-driven pattern in color vision 
thresholds [8, 12]. Further prospective studies with a larger 
number of patients are needed for a better understanding of 
the changes in color vision with aging.
Results
We included 48 patients, 92 eyes in the study. Thirty-five 
patients were female and 13 patients were male, with a mean 
age of 58.0 years (range 34–79).
Forty-three patients (89.6% of all cases) had a bilateral 
involvement at the time of DON diagnosis, and the remain-
ing 6 patients (10.4% of all cases) had unilateral involve-
ment. Five patients had a diagnosis of asthma, 8 patients had 
diabetes, and 9 patients had high blood pressure as accom-
panying conditions to Graves’ disease.
Nineteen patients were current-smokers, 9 patients were 
ex-smokers, and 17 had no smoking history (n = 45 patients). 
The fT3 was 2.88  µg/dl on average (range 0.90–5.80, 
n = 35), fT4 was 2.98 µg/dl (range 0.50–22.80, n = 35), 
and thyroid-stimulating hormone (TSH) was 3.67 μU/ml 
(range 0–34.00, n = 43). The mean TSH-receptor antibody 
(TRAB) was 19.40 mIU/ml (range 0.71–110.00, n = 43); 
the mean intraocular pressure (IOP) was 18.5 mmHg (range 
12–32 mmHg, n = 91 eyes) at the time of the DON diagnosis.
A total of 84 eyes had visual field defects compatible 
with DON, while 7 eyes had no VF defects at the time of the 
diagnosis; due to the retrospective design of the study, the 
VF of one eye was missing. The mean deviation (MD) of the 
VF was − 8.1 on average (range − 32.9 to 1.3, n = 91 eyes). 
The mean PSD was 4.88 (range 0.60–11.40, n = 91 eyes).
The summary of the demographic profiles and clinical 
findings can be seen in Table 1.
At the time of the DON diagnosis, 26 eyes (12 patients) 
had an optic disc edema, and 10 patients (16 eyes) had a 
positive swinging-flash-light test.
The mean BCVA was 0.42 LogMAR (range 0–2.0), with 
22 patients (41 eyes) displaying a BCVA ≤ 0.2 LogMAR.
The mean clinical activity score (CAS) was 5.6 (range 
1–8, n = 92 eyes). The mean protan value was 27.7% (range 
1.4–100%, n = 92 eyes), with 57 eyes (30 patients) showing 
a pathological protan value exceeding the threshold of ≥ 8%.
The most striking finding came from the tritan values 
(mean = 41.6%, range 6.3–100%, n = 91). All 48 patients and 
91 eyes, except for one eye, displayed the same pathological 
sign of tritan deficiency (exceeding the accepted threshold 
of 8%) at the time of the DON diagnosis. There was only 
one eye with a normal tritan value of 6.3%. This sign was 
observed regardless of the presence of VF defects or any 
changes in BCVA. Indeed, 41 eyes had a relatively good 
BCVA with ≤ 0.2 LogMAR. While BCVA (LogMAR) val-
ues certainly correlated with tritan and protan values at a 
statistically significant level (both p < 0.0001, Pearson cor-
relation coefficient), that correlation was far from perfect. 
Thus, tritan was able to point to a pattern that was undetect-
able with BCVA or protan alone.
We also calculated the sensitivity of the protan and tritan 
test, and 95% confidence interval was calculated using the 
Clopper-Pearson method. While the sensitivity of protan 
remained at 61.9% (95% CI: 51.2–71.8%), that of tritan was 
a remarkable 98.9% (95% CI 94.1–99.9%).
Discussion
The diagnosis of the dysthyroid optic neuropathy (DON) 
in thyroid-associated orbitopathy (TAO) is based on many 
clinical features including decreased BCVA, changes in 
color vision, relative afferent pupillary defect (RAPD), optic 
disc edema, VF defects, apical crowding on CT images, and 
reduced amplitude on visual-evoked potentials [13, 14]. Lack 
of standardized diagnostic criteria is a major impediment to 
timely diagnosis and treatment of DON. Existing diagnostic 
tools, such as visual field (VF) examination, color vision, and 
visual acuity tests, not only require patient cooperation, but 
also are largely subjective and easily influenced by coexisting 
corneal problems and motility of the eye (e.g., double vision) 
seen in TAO patients. The diagnosis of DON is especially 
challenging for patients who display no or minimal change in 
BCVA and VF. This study evaluated color vision tests as an 
alternative tool for identifying neuro-ophthalmic pathology, 
which can be missed in tests for visual acuity or visual field.
Many studies have examined clinical features of DON, 
and documented changes in color vision in patients with this 
condition. Yet, these changes have not been systematically 
evaluated to date. Our study analyzes the full spectrum of 
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findings from color vision test by Arden in a large sample 
of patients (n = 48 patients, 92 eyes) diagnosed with DON. 
We focus on a particular modality, computerized color test 
by Arden, which allows for precise and fast detection of 
individual color vision along the protan and tritan axes.
A number of studies have noted the importance of color 
vision deficiency in the detection of DON [5, 12, 15]. In 
McKeag et al.’s study for example, 80% of the patients with 
definite DON displayed reduced color vision as opposed 
to 56% of the patients with equivocal DON and 7% of the 
patients without any clinical signs of the condition. Based on 
this observation, the authors concluded that impaired color 
vision, along with optic disc swelling and radiological evi-
dence of apical optic nerve compression, can be a useful 
parameter in confirming DON diagnosis [15].
Neigel et al. investigated clinical features of DON with 
a large case series of 58 patients (95 eyes) diagnosed with 
the condition. According to their results, the authors found 
the Farnsworth-Munsell 100-hue test to be a sensitive indi-
cator for color discrimination in DON patients. Yet, the 
authors also used pseudoisochromatic screening procedures 
(Ishihara and Dvorine plates) and found that those proce-
dures rarely identified the acquired color defects in DON 
patients unless optic neuropathy was severe. According 
to the authors, the most sensitive indicators of optic nerve 
dysfunction in DON patients appeared to be visual-evoked 
potentials and color vision. Interestingly, the results never-
theless showed a main symptom of differentiated patients 
with DON was graying of vision, or desaturation of colors 
in optic neuropathy patients. The patients rarely voluntarily 
reported this symptom unless specifically asked [5].
Our results, based on 48 patients and 92 eyes, are gener-
ally in line with McKeag et al. and Neigel et al. in pointing 
to color deficiency as a sign of DON. Our findings, how-
ever, are more specific in identifying the particular forms 
of color deficiency in DON patients compared to earlier 
reports. We observed a pathological protan value (exceeding 
the threshold of 8%) in 30 patients (57 eyes) at the time of 
DON diagnosis. Remarkably, we discovered a pathological 
tritan deficiency (based on the same threshold of 8%) in all 
eyes except for one eye (91 eyes of the 48 patients). Put dif-
ferently, while the sensitivity of protan measure was 61.9% 
(95% CI 51.2–71.8%), that of tritan was an impressive 98.9% 
(95% CI 94.1–99.9%).
Today Ishihara plates remain the most popular method for 
testing color vision deficiency. The method is simple, easy 
to use, time sparing, and useful for the screening red-green 
congenital deficiency. Yet the method is not ideal for testing 
acquired color deficiency since it cannot quantify the sever-
ity, or identify the blue-yellow deficiency [16, 17].
Our results might be relevant to a broader area of dis-
eases which cause changes in color vision especially tritan 
deficiency such as optic neuritis, macular diseases, media 
opacity, dominantly inherited juvenile optic atrophy (DIJOA), 
and amblyopia [18, 19]. It is important to mention that there 
are a broad spectrum of hereditary diseases strongly related 
with blue-yellow deficiency such as DIJOA and congenital 
tritanopia [19].
For example, Almog et al. documented color vision loss 
as an outcome of optic neuropathy even among patients 
with a good-to-moderate visual acuity (VA). This finding is 
all the more striking given that the authors rely on Ishihara 
plates for testing color vision, which is limited in identifying 
acquired color deficiency. Although the focus of our study 
detailed above was on a different condition (DON) and relied 
on a different color vision test (by Arden), we observed a 
similarly striking pattern. Ninety-one eyes (out of 92 eyes) 
in our data display pathological values of tritan, even the 41 
eyes that had a relatively good BCVA of ≤ 0.2 LogMAR.
We conclude that tritan deficiency may indicate the optic 
nerve compression in patients with DON. Research sug-
gests tritan deficiency to be one of the most common forms 
of acquired vision loss. Jafarzadehpur et al., for instance, 
observed tritan deficiency in 66.1% of their cases with 
acquired color vision loss. Similarly, tritan (blue-yellow) 
deficiency is linked to retinal diseases in one of the earliest 
classification of color vision loss, dating back to 1912, while 
protan (red-green) deficiency is associated with optic nerve 
pathology [20]. Current research recognizes many excep-
tions to this generalization, also known as the Köllner’s rule, 
and is particularly suspicious of its applicability to optic 
neuropathies, such as optic neuritis [21].
Today, the Verriest classification—based on a retrospec-
tive analysis of 544 eyes—is the gold-standard classifica-
tion for acquired vision deficiencies [22]. In this scheme, 
tritan (blue-yellow) deficiency (defined as Verriest type III 
color vision deficiency) is linked to vascular retinopathies, 
papilledema, glaucoma, and dominant optic atrophy, but not 
yet to DON.
Our study presents evidence for the potential importance 
of tritan deficiency in the diagnosis of DON. Most impor-
tantly, we showed that tritan deficiency can help detect 
DON even in cases with little vision loss. A total of 17 DON 
patients (41 eyes) in our data had a relatively good BCVA 
score of ≤ 0.2 LogMAR, but they all showed pathological 
tritan values. Indeed, the sensitivity of tritan was 98.9% in 
our study (compared to only 61.9% of protan). Clinical diag-
nostics could use tritan tests to confirm a suspected DON 
diagnosis, and also to potentially detect patients early before 
they display any signs of vision loss.
Our sample is relatively large (n = 48 patients, 92 eyes) 
considering the rarity of the disease yet a larger sample 
size and prospective study design would be useful in con-
firming our findings. Our method of choice (Arden color 
vision test), although being not a well-known test method 
for color vision, is not the only means by which to detect 
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tritan deficiency. A limitation of our research was not hav-
ing a control group due to the retrospective design of the 
study. Future work could evaluate alternative tests for blue-
yellow deficiency in detecting optic nerve compression 
DON patients. Regardless of the method, we argue that a 
color vision test that can detect tritan deficiencies may be 
an essential and sensitive tool for the adequate assessment, 
diagnosis, and treatment of DON.
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